301075 Stock Overview
Engages in the research and development, production, and sale of chemical pharmaceutical preparations and its raw materials in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Tibet Duo Rui Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥25.29 |
| 52 Week High | CN¥34.50 |
| 52 Week Low | CN¥13.05 |
| Beta | -0.17 |
| 1 Month Change | 17.46% |
| 3 Month Change | 29.03% |
| 1 Year Change | 28.70% |
| 3 Year Change | -8.14% |
| 5 Year Change | n/a |
| Change since IPO | -43.69% |
Recent News & Updates
Recent updates
Some Confidence Is Lacking In Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) P/S
Mar 20
What Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) 41% Share Price Gain Is Not Telling You
Oct 09Tibet Duo Rui Pharmaceutical's (SZSE:301075) Solid Earnings May Rest On Weak Foundations
May 01Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) Stock Rockets 44% As Investors Are Less Pessimistic Than Expected
Mar 08Shareholder Returns
| 301075 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.2% | 1.6% | 0.7% |
| 1Y | 28.7% | 0.8% | 7.4% |
Return vs Industry: 301075 exceeded the CN Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: 301075 exceeded the CN Market which returned 7.4% over the past year.
Price Volatility
| 301075 volatility | |
|---|---|
| 301075 Average Weekly Movement | 12.3% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 10.4% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 301075's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301075's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 484 | Yong Deng | www.duoruiyy.com |
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations and its raw materials in China. It offers fluid therapy, anesthesiology, analgesic, and first-aid medication products.
Tibet Duo Rui Pharmaceutical Co., Ltd. Fundamentals Summary
| 301075 fundamental statistics | |
|---|---|
| Market cap | CN¥2.00b |
| Earnings (TTM) | -CN¥75.73m |
| Revenue (TTM) | CN¥211.61m |
9.4x
P/S Ratio-26.4x
P/E RatioIs 301075 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301075 income statement (TTM) | |
|---|---|
| Revenue | CN¥211.61m |
| Cost of Revenue | CN¥142.51m |
| Gross Profit | CN¥69.10m |
| Other Expenses | CN¥144.83m |
| Earnings | -CN¥75.73m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 32.66% |
| Net Profit Margin | -35.79% |
| Debt/Equity Ratio | 81.9% |
How did 301075 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 09:58 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tibet Duo Rui Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.